Prognostic factors from a randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and cisplatin in metastatic or recurrent cervical cancer: Japan Clinical Oncology Group (JCOG) trial: JCOG0505-S1
详细信息 查看全文
- 作者：Shin Nishio ; Ryo Kitagawa ; Taro Shibata…
- 关键词：Cervical cancer ; Metastatic ; Recurrent ; Platinum ; free interval ; Pretreatment hemoglobin level
- 刊名：Cancer Chemotherapy and Pharmacology
- 出版年：2016
- 出版时间：October 2016
- 年：2016
- 卷：78
- 期：4
- 页码：785-790
- 全文大小：427 KB
- 刊物类别：Biomedical and Life Sciences
- 刊物主题：Biomedicine
Cancer Research
Pharmacology and Toxicology
Oncology - 出版者：Springer Berlin / Heidelberg
- ISSN：1432-0843
- 卷排序：78
文摘
PurposeThe Japan Clinical Oncology Group (JCOG) trial JCOG0505 demonstrated the statistically significant non-inferiority of paclitaxel plus carboplatin (TC) to paclitaxel plus cisplatin (TP) in terms of overall survival (OS) in metastatic or recurrent cervical cancer. In that trial, patients were randomly assigned, adjusting for institution and known prognostic factors. The objective of this ancillary study was to evaluate the appropriateness of the adjustment factors used to have randomly assigned treatments and to investigate new potentially useful prognostic factors of paclitaxel plus platinum for future randomized trials in metastatic or recurrent cervical cancer.